BlackRock’s NewAmsterdam Pharma NAMS Stock Holding History

BlackRock’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$36.1M	Buy	1,063,750 +177,134	+20%	+$5.84M	﹤0.01%	2882
2026 Q1	$28.4M	Buy	886,616 +36,837	+4%	+$1.2M	﹤0.01%	2860
2025 Q4	$29.8M	Buy	849,779 +227,264	+37%	+$8.27M	﹤0.01%	2848
2025 Q3	$17.7M	Buy	622,515 +50,842	+9%	+$1.22M	﹤0.01%	3154
2025 Q2	$10.4M	Buy	571,673 +73,692	+15%	+$1.34M	﹤0.01%	3399
2025 Q1	$10.2M	Buy	497,981 +56,463	+13%	+$1.26M	﹤0.01%	3307
2024 Q4	$11.3M	Buy	441,518 +374,845	+562%	+$7.96M	﹤0.01%	3364
2024 Q3	$1.11M	Buy	66,673 +25,028	+60%	+$433K	﹤0.01%	4152
2024 Q2	$800K	Buy	41,645 +30,425	+271%	+$610K	﹤0.01%	4229
2024 Q1	$265K	Sell	11,220 -11,721	-51%	-$238K	﹤0.01%	4528
2023 Q4	$256K	Hold	22,941	–	–	﹤0.01%	4576
2023 Q3	$212K	Buy	+22,941	New	+$248K	﹤0.01%	4661

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

BlackRock's NAMS Position: Q2 2026 in Review

BlackRock increased its NewAmsterdam Pharma (NAMS) stake by 20% in Q2 2026, buying an estimated $5.84M and bringing the position to 1,063,750 shares worth $36.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2882.

BlackRock first reported a position in NAMS in Q3 2023 and has held it in 12 quarters since. 194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

BlackRock held 1,063,750 shares of NewAmsterdam Pharma worth $36.1M as of Q2 2026.
BlackRock bought 177,134 NewAmsterdam Pharma shares in Q2 2026, an estimated $5.84M.
NewAmsterdam Pharma made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #2882 holding.
BlackRock first reported a position in NewAmsterdam Pharma in Q3 2023 and has held it in 12 quarters since.
194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.